U.S. stocks concluded Wednesday, really unchanged.
The Dow Jones industrial average dropped down 4.24 points, or 0.02 percent, to 18,204.95, the S&P 500 declined 1.69 points, or 0.08 percent, to 2,113.79 and the Nasdaq Composite put in 1.92 points, or 0.04 percent, to 4,970.04.
Housing data was cheerful, after single-family home sales in January dropped down less than predictable and supply gained to its highest level since 2010.
As earnings season winds down, Thomson Reuters data through Wednesday morning showed that of the 465 companies in the S&P 500 that have posted earnings, 69 percent have topped expectations, matching the beat rate for the last four quarters but above the 63 percent rate since 1994.
Insights about some real movers of the market that remained most volatile, amid Thursday’s exchange are depicted underneath:
Signal Genetics, Inc. (NASDAQ:SGNL)’s shares skyrocketed 28.46% and led the share to close at $3.34, soon after a commercial stage, molecular genetic diagnostic company, declared the closing of its formerly declared underwritten public offering of 3,214,285 shares of its ordinary stock at a price to the public of $2.80 per share. Gross proceeds raised by Signal in the offering were $9,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Signal has granted the underwriters a 45-day option to purchase up to 482,142 shares of ordinary stock to cover over-allotments, if any.
Aegis Capital Corp. and Chardan Capital Markets, LLC acted as joint book-running managers for the offering.
Signal Genetics, Inc. (NASDAQ:SGNL), headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that assist physicians make better-informed decisions concerning the care of their patients suffering from cancer.
Shares of Aruba Networks, Inc. (NASDAQ:ARUN), jumped nearly 21.00% and closed at $22.24, soon after a leading provider of next-generation network access solutions for the mobile enterprise, declared that Karl Soderlund, vice president of worldwide channels and alliances, and Jim Harold, vice president of North America channels, have been named to the prestigious list of the 2015 CRN Channel Chiefs. The influential executives on this annual list represent the most powerful leaders in the IT channel who hold direct responsibility for driving growth and proceed for their organizations through their indirect channel partners.
Individuals are selected for inclusion based on their track record of channel accomplishments, standing in the industry, dedication to the partner community, and plans for driving future business innovation and channel growth. The 2015 CRN Channel Chiefs have demonstrated their enduring support for the channel by consistently defending, promoting and executing effective channel partner programs and strategies.
“Each year, our editors carefully vet an extensive group of highly accomplished channel executives to highlight those exemplary individuals who earn the mantle of CRN Channel Chief. These executives strive to advance the success and standing of the channel community within their organizations. The 2015 CRN Channel Chiefs lead by example and serve as valuable advocates to assist ensure the health and longevity of the IT channel. We applaud their accomplishments and look forward to their continued success,” said Robert Faletra, CEO, The Channel Company.
Aruba Networks, Inc. (NASDAQ:ARUN), is a leading provider of next-generation network access solutions for the mobile enterprise. The company designs and delivers Mobility-Defined Networks that empower IT departments and #GenMobile, a new generation of tech-savvy users who rely on their mobile devices for every aspect of work and personal communication.
ArQule Inc. (NASDAQ:ARQL), surged 22.22% to close at $1.65, soon after a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics, declared that it will report its financial results for the fiscal 2014 year-end and fourth quarter on Wednesday, March 4, 2015 at 7:00 a.m. eastern time. The Company will hold a conference call at 9:00 a.m. eastern time that day to talk about these results.
ArQule Inc. (NASDAQ:ARQL), is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers.
Shares of the IsoRay, Inc. (NYSE MKT:ISR), gained 19.86% & closed at $1.69, soon after a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, declared its financial results for the quarter and six months ended December 31, 2014. With over $20,000,000 of cash on hand and no debt, IsoRay is positioned to be a dominant player in the brachytherapy cancer treatment market.
IsoRay’s team remains focused in diversifying its product offerings through institutional based studies designed to address various aggressive cancers that to date often fail current standard of care options. Administration is hopeful that the lingering decline in the prostate market may be bottoming out. Administration anticipates seeing modest gains in IsoRay’s market share in addition to some proceed growth in the coming quarters. We practiced a negative influence on our international sales efforts during the quarter ended December 31, 2014, with the devaluation of the Euro causing our products to become higher in price, making it more difficult to attract new adopters in this market.
IsoRay, Inc. (NYSE MKT:ISR), through its partner, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which is expanding brachytherapy options throughout the body.
